Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.05 and last traded at C$0.04, with a volume of 29000 shares traded. The stock had previously closed at C$0.06.
Hemostemix Trading Up 33.3%
The firm has a market capitalization of C$12.30 million, a price-to-earnings ratio of -3.00 and a beta of 0.21. The company has a debt-to-equity ratio of -66.09, a current ratio of 0.24 and a quick ratio of 0.48. The firm’s 50-day simple moving average is C$0.06 and its 200 day simple moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Read More
- Five stocks we like better than Hemostemix
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
